Exclusive Summary

• - Fully off-patent, globally established molecule widely used for post‑operative ocular inflammation and pain control.
• - Core demand comes from cataract and refractive surgeries, creating roughly 34–41 million bottles of annual treatment opportunities (assuming ~1 bottle per case).
• - Endorsed by major guidelines (AAO/ESCRS) as part of standard NSAID regimens; listed on multiple national/WHO essential medicines lists with high clinical acceptance.
• - Competitive but fragmented market; reliable sterile capacity and multi-pharmacopoeia alignment enable faster entry and distributor-led scale-up.
• - Typically 50–90% cheaper than originators and newer ophthalmic NSAIDs, supporting tenders and out-of-pocket markets with strong cost-effectiveness.